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Abstract
Purpose—Failure of blood pressure (BP) to dip during sleep (non-dipper pattern) is associated 
with cardiovascular disease (CVD) and stroke. The prevalence and degree of non-dipping and 
masked hypertension in patients with retinal vein occlusion (RVO), which is associated with 
stroke, has not been previously examined.
Methods—We measured clinic and 24-hour ambulatory BPs in 22 patients with RVO and 20 
control participants without known eye disease matched by age and sex. Mean BP dipping, defined 
as the ratio of difference in mean awake and sleep systolic BPs to mean awake systolic BP, and 
masked and nocturnal hypertension were compared between groups.
Results—Mean 24-hour ambulatory BP was 144/79 mmHg among those with RVO and 136/77 
mmHg among controls. Patients with RVO had an almost two-fold higher prevalence of non-
dipping pattern (80.8% (95% CI 52.8, 94.1) vs. 50.4% (95% CI 26.1, 74.5);p=0.008). Average 
sleep systolic BP dip in RVO patients was 6.1% vs. 11.9% in controls (p=0.004). More RVO 
patients had masked hypertension by ambulatory BPs than controls (71% vs. 50%), but this 
difference was not statistically significant.
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Conclusion—Our data suggest an association between RVO and non-dipper BP pattern. 
Ambulatory BP monitoring may be useful in the evaluation of patients with RVO by identifying 
those who may benefit from more aggressive BP control.
Keywords
Retinal Vein Occlusion; Ambulatory Blood Pressure Monitoring; Non-Dipper; Cardiovascular 
Disease Risk; Epidemiology; Diagnostic Tests
Introduction
Hypertension is a well-known risk factor for patients with retinal vein occlusion (RVO),1–4 
but diagnosing hypertension in RVO patients based on office blood pressure (BP) 
measurements alone can miss patients with uncontrolled hypertension. Uncontrolled 
hypertension may manifest as masked hypertension, defined as normal BP in the office 
setting but elevated BP based on out-of-office BP measurements. Masked hypertension is 
associated with increased target-organ damage and poor cardiovascular prognosis.5,6 Out-of-
office measurements of BP can be obtained by 24-hour ambulatory BP monitoring, whereby 
the patient wears a portable device (Figure 1) that automatically records BP at pre-specified 
intervals. Masked hypertension may manifest as elevated BP during sleep, which has been 
shown to be a better predictor of cardiovascular outcomes than daytime BP alone, and is 
currently detectable only by 24-hour ambulatory BP monitoring.7,8
Ambulatory BP monitoring demonstrates that BP typically exhibits a circadian rhythm with 
a decrease during sleep (dipper pattern). Studies have shown the absence of a nocturnal 
decrease (non-dipper) or presence of a nocturnal rise in BP (riser pattern) to be 
independently associated with increased risk of cardiovascular events and strokes.910
Ambulatory BP monitoring may be valuable in RVO patients because it can identify those 
with masked hypertension or those with non-dipping, which is a risk factor for 
cardiovascular mortality even if overall BP average is not elevated.7 In a Brazilian study, 
which used ABPM to evaluate for masked hypertension in RVO patients, 92% (76) of 
patients with branch RVO had hypertension. Further examination of nocturnal BP 
measurements revealed that half of those with hypertension exhibited non-dipper patterns.11 
Improved identification and treatment of hypertension among patients with RVO has the 
potential benefit in the management of RVO via concurrent management with primary care 
to reduce recurrent or subsequent stroke and CVD events. We therefore performed a cross-
sectional study assessing 24-hour BP control and non-dipper pattern as well as secondary 
characteristics, such as the presence of masked hypertension and nocturnal hypertension, in 
patients with RVO compared to age and sex-matched controls.
Methods
Overall Design
We conducted a cross-sectional study using convenience sampling and chart review. This 
study was approved by the University of North Carolina Institutional Review Board (IRB), 
and informed consent was obtained from each participant. The study complied with all 
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aspects of the Health Insurance Portability and Accountability Act (HIPAA) and adhered to 
the tenets of the Declaration of Helsinki.
Study Participants
Inclusion criteria were patients seen at University of North Carolina Ophthalmology 
between January 2011 and May 2014 with a diagnosis of RVO. Seventy-six patients with 
RVO were identified by ICD-9 code (362.36 (branch RVO), 362.35 (central RVO-complete), 
362.37(central RVO-partial), 362.30 (retinal vascular occlusion, unspecified), 362.37 
(venous engorgement)) through UNC’s electronic medical record. Patients with RVO 
diagnosed greater than 12 months previously were initially excluded but later included to 
broaden participant enrollment. Patients younger than 45 years of age at the time of RVO 
and patients with known or suspected hypercoagulable states were excluded from the study.
A study recruiter contacted the patients via telephone. Eighteen of those contacted were 
interested in participating of which 7 were finally recruited. Of the 33 patients who declined, 
2 were deceased, 3 cited time limitations, 3 cited transportation limitations, 8 were not 
interested and 19 did not return the recruiter’s phone call. An additional 15 patients were 
recruited as they presented or referred to clinic during this time frame, resulting in a total of 
22 patients who agreed to participate in this study.
Controls were selected from a prior University of North Carolina study database of 
participants without known eye disease who underwent ambulatory BP monitoring to assess 
the reproducibility of masked hypertension among borderline hypertensives.14 The controls 
were matched by age and sex, masked to their BP level and dipping status. These controls 
were recruited after measuring clinic blood pressures to evaluate the identification of masked 
hypertension using ABPM.
Clinic Blood Pressure Measurements
Clinic BP measurements were obtained prior to fitting participants with the ambulatory BP 
monitor. Three seated, non-dominant arm BP measurements were recorded at one-minute 
intervals using an appropriate cuff size after an initial 5 minutes of rest.
Ambulatory Blood Pressure Monitoring
Ambulatory blood pressure monitoring (ABPM) was performed over a 24-hour period using 
an Oscar 2 ambulatory BP monitoring device (Suntech Medical, Morrisville, NC). The 
Oscar 2 ABPM has been previously validated.12 The same ambulatory blood pressure 
instrumentation, methods, and analysis for RVO patients and controls. The BP cuff was 
worn on the non-dominant arm with the cuff size determined by upper arm circumference, 
and an in-office test measurement was performed to assess adequate fit and comfort. The 
device was programmed to take measurements at 30 minute intervals from 6am to 10pm and 
at 60 minute intervals from 10pm to 6am. BP readings were set at slightly variable time 
intervals to prevent anticipation effect. Any values that were outside preset limits (systolic 
≥220 or ≤80 mmHg; diastolic ≥130 or ≤40 mmHg) were rejected, and a repeat measurement 
was recorded.
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We used a participant diary to define sleep and awake periods and to note activities that may 
influence the fluctuation in daytime and nighttime BP. If a diary was not available, 
participants were asked the times they went to sleep and awoke at the time of follow-up the 
next day. If participants did not provide this information, we defined awake as 10am to 
10pm and sleep as midnight to 6am. The ambulatory BP monitoring measurements were 
downloaded from the portable unit to a computer for summary and analysis. We minimized 
confounding factors that may influence ABPM results by asking participants about any 
events at night and sleep quality. If there was concern about poor sleep, such as using the 
restroom at night or leaving the bedroom to eat or read, we removed any isolated 
measurements that corresponded with those events and any outlier readings (diastolic BP 
<30 mm Hg, pulse pressure < 20 mm Hg, or isolated diastolic BP > 120 mm Hg with no 
other diastolic readings > 110 mm Hg) that could influence the averaged nocturnal and 
awake BP measurements. Following this procedure, we required a minimum of 14 awake 
and 6 sleep measurements to deem a session adequate, following protocol previously 
performed in other studies assessing nighttime dipping.13
Definitions
Following prior ABPM protocols, masked hypertension was defined as normal clinic BPs 
(BPs <140/90) with elevated awake ambulatory BPs (systolic BP ≥ 135 mmHg or diastolic 
BP ≥ 85 mmHg) or elevated sleep ambulatory BPs (systolic BP ≥ 120 mmHg or diastolic BP 
≥ 70 mmHg).10,14 Nocturnal hypertension was defined as sleep ambulatory systolic BP ≥ 
120 mmHg or diastolic BP ≥ 70 mmHg.14 Non-dipping was defined as dipping ≤10%.13
Statistical Analysis
BP dipping was calculated as the ratio of difference in mean awake and sleep systolic BPs to 
mean awake systolic BP. For example, if the participant had a mean awake systolic BP of 
150 mmHg and a mean sleep systolic BP of 130 mmHg, the average systolic 
. Patients with RVO were 
compared to the non-RVO participants using the two-sample Student’s t-test for continuous 
variables and Chi-square or Fisher’s Exact test for categorical variables. Analysis of 
covariance (ANCOVA) with a regression model was used to assess the relationship of 
diagnosis of RVO on the outcome of prevalence of non-dipping versus dipping status. 
Covariates that had a relatively equal distribution were omitted, and the final adjusted 
variables included race, smoking status, and diabetes. A second model was performed to 
include hypertension with the other covariates. All statistical analyses were performed using 
Stata 13 (StataCorp LP, College Station, Texas).
Results
Characteristics of Sample
Of 76 patients identified with RVO, 22 elected to participate and underwent ABPM. Two 
participants were later excluded due to inadequate number of sleep measurements. The mean 
age of participants with RVO was 68.9 years (Table 1). Five out of 20 (25%) were male. The 
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mean clinic BP was 151/85 mmHg among those with RVO and 129/78 mmHg among the 
comparison group.
BP Dipping
The ambulatory BP averages are shown in Figure 2. Seven RVO participants and 6 control 
participants did not provide an activity and sleep diary. These participants provided times of 
sleep and awakenings upon follow-up the next day. The mean (±SD) 24-hour ambulatory BP 
was 144/79 mmHg (±17/9 mmHg) among those with RVO and 136/77 mmHg (±12/9 
mmHg) for the comparison group. The average systolic BP dipping ratio was 6.1% among 
those with RVO compared to 11.9% among those without RVO (p=0.004). Seventeen out of 
the 20 participants with RVO were non-dippers (85%) compared to 9 out of 20 controls 
(45%; p=0.008; Table 2). After adjusting for race, smoking status, and diabetes, the 
difference in non-dipper prevalence was 83.5% vs. 44.3% (p=0.021). When hypertension 
was also included in a second model, the difference remained statistically significant (84.4 
vs. 45.2%; p=0.026).
Three participants with RVO exhibited a riser pattern, defined as average nighttime BPs 
exceeded average daytime BPs. Two of the 3 participants with RVO who exhibited nocturnal 
systolic BP dipping had elevated daytime systolic BPs. Six of the 8 participants with RVO 
who were not on antihypertensive treatment were non-dippers (75%). In addition, of the 7 
participants with RVO who had normotensive office visit BP measurements, defined as 
clinic BP measurements <140/90 mmHg, 4 (57%) exhibited non-dipper patterns. Twelve of 
13 participants with RVO who also had hypertension identified by office measurements were 
non-dippers (92%).
Masked Hypertension and Nocturnal Hypertension
Ambulatory measurements revealed elevated BPs among patients with RVO who had 
normotensive office visit BP measurements, as shown in Table 3. Five of 7 with RVO (71%) 
had masked hypertension by ambulatory measurements. Seventeen of 20 patients with RVO 
and 13 of 20 control participants had nocturnal hypertension (85 vs. 65%). Interestingly, 
among those who had nocturnal hypertension, 1 of 17 RVO patients (5%) and 5 of 13 
control patients (38%) exhibited a dipper pattern.
Discussion
RVO is often associated with systemic diseases such as hypertension, hyperlipidemia, 
diabetes, coronary artery disease, and smoking.3,15–17 Hypertension is a known risk factor 
for CVD morbidity and mortality.18 While RVO is not an independent risk factor for 
cardiovascular or stroke-related mortality, patients with RVO have a high risk of 
hypertension (48%-85%) and an increasing trend in incident strokes.17,19–22, 24, 27 A recent 
longitudinal study showed an increased risk of stroke in individuals with RVO versus the 
comparison group (16.8% vs 10.7%). 23 Central RVO has been associated with increased 
mortality that is likely attributable to systemic cardiovascular disorders.21, 24, 27
RVO is considered end-organ damage in hypertensive disease. Currently, most diagnoses of 
hypertension are based solely on office readings, but office BP measurements alone may 
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failed to identify patients with nocturnal or masked hypertension, which is diagnosed with 
ambulatory BP monitoring. This subset of patients would be susceptible to CVD and stroke-
related mortality secondary to unidentified hypertension. Studies have demonstrated that 
ambulatory nighttime (sleep) BP non-dipper patterns are strong predictors of CVD and 
stroke risk.9,10 Better nocturnal BP control could improve mortality in patients with non-
dipper patterns.10 Antihypertensive chronotherapy, the administration of antihypertensive 
regimens based on the circadian diurnal pattern, has been shown to significantly lower the 
incidence of CVD death, myocardial infarction, and strokes.25
In this cross-sectional study, patients with RVO had a nearly two-fold higher prevalence of 
non-dipping nocturnal BP pattern than participants from a non-RVO comparison group. This 
held true after adjusting for race, smoking, diabetes, and hypertension. When also 
accounting for differences in participants with hypertension between both groups, the 
difference in non-dipper rates persisted. This increased rate of non-dipping status in RVO 
patients likely reflects unidentified hypertension in this population.
Our control group was selected because they had the identical ABPM instrumentation and 
methods performed, and had no known eye disease. Of note, our comparison group had a 
45% rate of non-dippers, which is higher than the 20% rate reported in the general 
population.10 We identified more patients with normotensive clinic BPs who exhibited non-
dipping, and thus elevated nocturnal blood pressures, which would have otherwise gone 
undetected by clinic BPs alone (57%). We also identified more patients who exhibited 
masked hypertension based on overall ABPM measurements (71%). Interestingly, we also 
found that 92% of patients with RVO who had a known diagnosis of hypertension also had a 
non-dipping status, which is higher than the previously reported prevalence of non-dippers 
among hypertensive patients (54%).25 Even though the vast majority of these patients were 
already on antihypertensive medications, the high prevalence of non-dipping is surprising 
because it is a risk factor for cardiovascular mortality and stroke independent of office BP 
measurements.7,25 ABPM is increasingly being recognized as an important component of 
modern hypertension diagnosis and management.27 If ABPM proves to be useful in CVD 
risk stratification of RVO patients, it would expand the evidence-base for uses of this 
technology.
To our knowledge, this is the first study designed to examine the prevalence of non-dipping, 
degree of dipping, in addition to masked hypertension among patients with RVO compared 
to those without eye disease. Given that some study participants had normal clinic BP while 
exhibiting a non-dipping BP pattern and/or masked hypertension further suggests that 
ABPM may be an important component of the evaluation of a patient with RVO. The 
importance of nocturnal non-dipping status in addition to daytime hypertension in relation to 
CVD and associated morbidity7,10 including RVO warrants further investigation. Additional 
studies are warranted to fully characterize dipping patterns among RVO patients and it’s 
associated clinical relevance to both ocular and systemic morbidity.
We present the hypothesis that ABPM for RVO patients could be used to identify and risk 
stratify patients who do not have adequate BP control and who might benefit from additional 
or alternate timing of antihypertensive treatment to reduce morbidity and mortality from 
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CVD. Better 24-hour BP control may help reduce mortality from CVD and stroke in RVO 
patients.25 Our study is limited by its small sample size. Although we were only able to 
successfully recruit 18% (7/40) of those patients identified by CPT code and contacted by a 
recruiter in addition to patients presenting to clinic, our results could be biased by an 
unidentified inherent difference in those agreeing to participate versus those declining. 
However, we believe such difference would be unlikely to affect the results away from the 
null. Also, the use of convenience sampling may limit the generalizability of our results to a 
broader population due to differences in sample characteristics and the general population. 
The use of diaries in some participants may introduce measurement bias in defining rest and 
activity periods during 24-hour ABPM; however, we attempted to reduce such bias by 
asking the remaining participants their awake and sleep times. We recognize that part of the 
RVO group receiving antihypertensive treatment may influence the results, although this 
would likely bias the difference in sleep blood pressure patterns towards the null. We also 
acknowledge that there are no definitive recommendations on the frequency of awake and 
sleep measurements in assessing nighttime dipping. We used the 14 awake and 6 sleep 
measurements as a balance of feasibility while providing a reasonable depiction of average 
BPs during sleep, as has been done in studies using CARDIA data.13
Our small pilot study identified a statistically significant higher prevalence of non-dippers in 
the RVO group compared to the controls. We believe additional large studies are warranted 
to further examine the relationship between RVO and 24-hour BP. The identification of a 
relationship between masked hypertension or nocturnal non-dipping status and RVO 
occurrence can serve as a mode for ophthalmologists to assist primary care in the reduction 
of systemic morbidity and mortality in a shared patient population. In addition, ABPM may 
also be beneficial in patients with other ocular stigmata of hypertensive retinopathy without 
RVO, such as retinal macroaneurysm and ischemic optic neuropathy, but additional studies 
are needed.28
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Figure 1. Ambulatory Blood Pressure Monitor
Legend: An ambulatory blood pressure monitor is a standard portable digital blood pressure 
(BP) device that records BP measurements over a 24-hour period. The various blood 
pressure cuff sizes can match individual arm circumference for accuracy of BP readings and 
patient comfort (Fig 1A). The device is portable and fits securely in a pouch either on a belt 
or waist strap, and the connecting cord slips under the patient’s garment (Fig 1B). The blood 
pressure cuff can rest under clothing without restricting the patient’s daily activities (Fig 
1C).
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Figure 2. Ambulatory Systolic Blood Pressure Measurements by Presence of Retinal Vein 
Occlusion
Legend: BP, blood pressure; SBP, systolic blood pressure.
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Table 1
Demographic and Clinical Characteristics of Participants Stratified by Presence of Retinal Vein Occlusion
RVO*
(n = 20)
Non-RVO
(n = 20)
Difference
(95% Confidence
Interval)
P-value‡
Age, mean yrs (± SD) 68.9 (8.4) 67.7 (7.6) 1.2 (−4.0, 6.4) 0.6
Male, n (%) 5 (25.0) 5 (25.0) n/a 1.0
Current Smoker, n (%) 6 (30.0) 1 (5.0) n/a 0.091**
Caucasian, n (%) 17 (85.0) 17 (85.0) n/a 1.0**
Diabetes Mellitus, n (%) 3 (15.0) 0 (0) n/a 0.23**
Glaucoma, n (%) 5 (25.0) 0 (0) n/a 0.047**
Baseline Clinic SBP, mean mmHg (± SD) 151.4 (21.1) 129.0 (17.4) 22.4 (10.0, 34.8) 0.0008
Baseline Clinic DBP, mean mmHg (± SD) 85.4(10.6) 78.3(12.6) 7.2 (−0.2, 14.6) 0.058
Clinic Pulse Pressure, mean mmHg (± SD) 65.9 (17.2) 50.7 (11.0) 15.2 (−6.0, 24.5) 0.002
Hypertension, n (%)† 13 (65.0) 6 (30.0) n/a 0.027
Antihypertensive treatment 12 (60.0) 0 (0) n/a <0.001**
*
Total, n = 40; RVO, n = 20; Control, n = 20. BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; Pulse Pressure, as 
defined as systolic pressure minus diastolic pressure
†
Based on clinic SBP ≥ 140 mmHg or DBP ≥ 90 mmHg
‡
Based on two-sample Student’s T-test for continuous variables, Pearson’s Chi-square test for categorical variables
**
Based on Fisher’s Exact test since at least one cell has expected count less than five
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Table 2
Mean Ambulatory Blood Pressures by Presence of Retinal Vein Occlusion
RVO*
(n = 20)
Non-RVO
(n = 20)
Difference
(95% CI) P-value
†
24-h Ambulatory SBP, mean mmHg (± SD) 144.3 (16.6) 135.9 (12.0) 8.4 (−0.8, 17.6) 0.074
24-h Ambulatory DBP, mean mmHg (± SD) 79.4 (8.6) 76.8 (9.3) 2.6 (−3.1, 8.3) 0.37
Awake SBP average, mean mmHg (± SD) 146.2 (16.1) 139.6 (11.3) 6.65 (−2.3, 15.6) 0.14
Sleep SBP average, mean mmHg (± SD) 138.4 (19.8) 123.1 (15.2) 15.3 (3.9, 26.6) 0.010
Awake DBP average, mean mmHg (± SD) 81.0 (7.9) 79.6 (9.8) 1.4 (−4.3, 7.1) 0.63
Sleep DBP average, mean mmHg (± SD) 74.4 (11.9) 67.8 (8.6) 6.7 (0.1, 13.3) 0.047
Average Systolic BP Dip, % (mean ± SD) 6.1 (6.2) 11.9 (5.8) −5.8 (−9.7, −2.0) 0.004
Proportion of Non-dippers, % (n) 85.0 (17) 45.0 (9) n/a 0.008‡
Adjusted proportion of Non-dippers, % (95% Confidence Interval) 83.5 (57.9, 94.9) 44.3 (23.3, 67.5) n/a 0.021**
Adjusted proportion of Non-dippers, % (95% Confidence Interval) 84.4 (57.9, 95.5) 45.2 (23.0, 69.5) n/a 0.026††
Adjusted proportion of Non-dippers, % (95% Confidence Interval) 80.8 (52.8, 94.1) 50.4 (26.1, 74.5) n/a 0.102‡‡
*
Total, n = 40; RVO, n = 20; Control, n = 20. BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; BP Dip, nocturnal 
blood pressure dipping ratio as we defined as the ratio of change in mean daytime and nighttime systolic blood pressures to mean daytime systolic 
blood pressure
†
Based on two-sample Student’s T-test by presence of RVO
‡
Based on Pearson’s Chi-square test
**Adjusted for race, diabetes, and smoking status
††Adjusted for race, diabetes, smoking status, and hypertension
‡‡Adjusted for race, diabetes, smoking status, and continuous clinic SBP variable
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Table 3
Masked Hypertension and Nocturnal Hypertension by Presence of Retinal Vein Occlusion
RVO
(n = 7)
Non-RVO
(n = 14) P-value
**
Masked Hypertension by awake and sleep BPs, n (%)† 5 (71) 7 (50) 0.64
Nocturnal Hypertension, n (%)*,‡ 17 (85) 13 (65) 0.27
*
Total, n = 40; RVO, n = 20; Control, n = 20. BP, blood pressure.
†
Based on awake ambulatory systolic BP ≥ 135 mmHg or diastolic BP ≥ 85 mmHg or sleep ambulatory systolic BP ≥ 120 mmHg or diastolic BP ≥ 
70 mmHg
‡
Based on sleep ambulatory systolic BP ≥ 120 mmHg or diastolic BP ≥ 70 mmHg
**
Based on Fischer’s Exact test
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